Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
No relationship between-141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: a preliminary study
Autore:
Mihara, K; Kondo, T; Suzuki, A; Yasui, N; Ono, S; Otani, K; Kaneko, S;
Indirizzi:
Hirosaki Univ, Sch Med, Dept Neuropsychiat, Hirosaki, Aomori 0368562, Japan Hirosaki Univ Hirosaki Aomori Japan 0368562 rosaki, Aomori 0368562, Japan Yamagata Univ, Sch Med, Dept Neuropsychiat, Yamagata 9902331, Japan Yamagata Univ Yamagata Japan 9902331 ropsychiat, Yamagata 9902331, Japan
Titolo Testata:
PSYCHIATRY RESEARCH
fascicolo: 1, volume: 101, anno: 2001,
pagine: 33 - 38
SICI:
0165-1781(20010214)101:1<33:NRBIPI>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
PROLACTIN RESPONSE; ACUTE DYSTONIA; IN-VIVO; NEMONAPRIDE; GENE; BROMPERIDOL; ASSOCIATION; BINDING; SERUM; DRUG;
Keywords:
dopamine D2 receptor; -141C Ins/Del polymorphism; extrapyramidal side effects; schizophrenia; bromperidol; nemonapride;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Life Sciences
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Mihara, K Hirosaki Univ, Sch Med, Dept Neuropsychiat, Hirosaki, Aomori 0368562, Japan Hirosaki Univ Hirosaki Aomori Japan 0368562 mori 0368562, Japan
Citazione:
K. Mihara et al., "No relationship between-141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: a preliminary study", PSYCHIAT R, 101(1), 2001, pp. 33-38

Abstract

Previous studies have shown that subjects without Del alleles of the -141CIns/Del polymorphism in the promoter region of the dopamine D2 receptor. (DRD2) gene have lower DRD2 density that those with one or two Del alleles. The present study aims to investigate the relationship between the -141C Ins/Del polymorphism and extrapyramidal adverse effects of bromperidol and nemonapride, antipsychotic drugs with a selective and potent DRD2 antagonistic property, in schizophrenic inpatients. Twenty-seven patients were treatedwith bromperidol at a fixed-dose of 6, 12 or 18 mg/day, and 25 patients were treated with nemonapride at a fixed-dose of 18 mg/day. The duration of treatment with these drugs was 3 weeks. The Ins and Del alleles were determined by PCR. Extrapyramidal adverse effects were assessed by the Udvalg for Kliniske Undersogelser side effects rating scale. The subjects consisted of38 homozygotes of the Ins allele and 14 heterozygotes of the Ins and Del alleles. There were no significant differences in the incidence or severity of extrapyramidal adverse effects between patients with and without the Delallele. It is possible that this result was due to a lack of statistical power. However, the present study suggests that the - 141C Ins/Del polymorphism is not related to the development of extrapyramidal adverse effects during acute-phase treatment with antidopaminergic agents. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 11:37:52